Indian pharmaceutical stocks witnessed a decline after Donald Trump’s warning to levy tariffs on pharmaceutical imports, leading to a 1.7% drop in the Nifty Pharma index. Key players like Gland Pharma and Sun Pharma faced notable setbacks. Trump’s announcement aimed at encouraging pharmaceutical firms to relocate manufacturing to the US using tariffs could potentially affect India’s significant generic drug exports to the US.
Trump’s Tariff Threat Causes Indian Pharma Stocks to Drop 1.7% on Nifty Index, Gland and Sun Pharma Hit.
In Trend
RBI cuts repo rate to 6%, shifts stance amid global uncertainties; GDP growth forecast lowered, inflation outlook benign.
